Výsledky vyhledávání - Ross, David M
- Zobrazuji výsledky 1 - 20 z 20
-
1
-
2
-
3
-
4
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features Autor Ross, David M., Bartley, Paul A., Goyne, Jarrad, Morley, Alexander A., Seymour, John F., Grigg, Andrew P.
Vydáno 2011Text -
5
Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study Autor Ho, P. Joy, Hiwase, Devendra, Ramakrishna, Raj, Viiala, Nicholas, Solterbeck, Ann, Traficante, Robert, Zor, Evren, Gervasio, Othon L., High, Laura M., Ross, David M., Bowden, Donald K.
Vydáno 2019Text -
6
Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study Autor Martin, Hilary Laura, Ullah, Shahid, Abbas, Nazim, Scott‐Hoy, Alex, Kichenadasse, Ganessan, Karapetis, Christos Stelios, Roy, Amitesh, Sukumaran, Shawgi, Ross, David M, Khattak, Muhammad Adnan, Koczwara, Bogda
Vydáno 2021Text -
7
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia Autor Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Vydáno 2018Text -
8
Targeting human CALR‐mutated MPN progenitors with a neoepitope‐directed monoclonal antibody Autor Tvorogov, Denis, Thompson‐Peach, Chloe A L, Foßelteder, Johannes, Dottore, Mara, Stomski, Frank, Onnesha, Suraiya A, Lim, Kelly, Moretti, Paul A B, Pitson, Stuart M, Ross, David M, Reinisch, Andreas, Thomas, Daniel, Lopez, Angel F
Vydáno 2022Text -
9
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study Autor Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Vydáno 2021Text -
10
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study Autor Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Vydáno 2021Text -
11
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis Autor Tvorogov, Denis, Thomas, Daniel, Liau, Nicholas P. D., Dottore, Mara, Barry, Emma F., Lathi, Maya, Kan, Winnie L., Hercus, Timothy R., Stomski, Frank, Hughes, Timothy P., Tergaonkar, Vinay, Parker, Michael W., Ross, David M., Majeti, Ravindra, Babon, Jeffrey J., Lopez, Angel F.
Vydáno 2018Text -
12
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study Autor Mascarenhas, John, Passamonti, Francesco, Burbury, Kate, El-Galaly, Tarec Christoffer, Gerds, Aaron, Gupta, Vikas, Higgins, Brian, Wonde, Kathrin, Jamois, Candice, Kovic, Bruno, Huw, Ling-Yuh, Katakam, Sudhakar, Maffioli, Margherita, Mesa, Ruben, Palmer, Jeanne, Bellini, Marta, Ross, David M., Vannucchi, Alessandro M., Yacoub, Abdulraheem
Vydáno 2022Text -
13
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome Autor Singhal, Deepak, Kutyna, Monika M., Chhetri, Rakchha, Wee, Li Yan A., Hague, Sophia, Nath, Lakshmi, Nath, Shriram V., Sinha, Romi, Wickham, Nicholas, Lewis, Ian D., Ross, David M., Bardy, Peter G., To, Luen Bik, Reynolds, John, Wood, Erica M., Roxby, David J., Hiwase, Devendra K.
Vydáno 2017Text -
14
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial Autor Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe
Vydáno 2021Text -
15
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib Autor Cheah, Chan Y., Burbury, Kate, Apperley, Jane F., Huguet, Francoise, Pitini, Vincenzo, Gardembas, Martine, Ross, David M., Forrest, Donna, Genet, Philippe, Rousselot, Philippe, Patton, Nigel, Smith, Graeme, Dunbar, Cynthia E., Ito, Sawa, Aguiar, Ricardo C. T., Odenike, Olatoyosi, Gimelfarb, Alla, Cross, Nicholas C. P., Seymour, John F.
Vydáno 2014Text -
16
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study Autor Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, Hochhaus, Andreas
Vydáno 2018Text -
17
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Autor Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.
Vydáno 2015Text -
18
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia Autor Bassal, Mahmoud A., Samaraweera, Saumya E., Lim, Kelly, Benard, Brooks A., Bailey, Sheree, Kaur, Satinder, Leo, Paul, Toubia, John, Thompson-Peach, Chloe, Nguyen, Tran, Maung, Kyaw Ze Ya, Casolari, Debora A., Iarossi, Diana G., Pagani, Ilaria S., Powell, Jason, Pitson, Stuart, Natera, Siria, Roessner, Ute, Lewis, Ian D., Brown, Anna L., Tenen, Daniel G., Robinson, Nirmal, Ross, David M., Majeti, Ravindra, Gonda, Thomas J., Thomas, Daniel, D’Andrea, Richard J.
Vydáno 2022Text -
19
Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia Autor Bassal, Mahmoud A., Samaraweera, Saumya E., Lim, Kelly, Benard, Brooks A., Bailey, Sheree, Kaur, Satinder, Leo, Paul, Toubia, John, Thompson-Peach, Chloe, Nguyen, Tran, Maung, Kyaw Ze Ya, Casolari, Debora A., Iarossi, Diana G., Pagani, Ilaria S., Powell, Jason, Pitson, Stuart, Natera, Siria, Roessner, Ute, Lewis, Ian D., Brown, Anna L., Tenen, Daniel G., Robinson, Nirmal, Ross, David M., Majeti, Ravindra, Gonda, Thomas J., Thomas, Daniel, D’Andrea, Richard J.
Vydáno 2022Text -
20
COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement Autor McCaughan, Georgia, Di Ciaccio, Pietro, Ananda‐Rajah, Michelle, Gilroy, Nicole, MacIntyre, Raina, Teh, Benjamin, Weinkove, Robert, Curnow, Jennifer, Szer, Jeff, Enjeti, Anoop K, Ross, David M, Mulligan, Stephen, Trotman, Judith, Dickinson, Michael, Quach, Hang, Choi, Phillip, Polizzotto, Mark N., Tam, Constantine S., Ho, P. Joy, Ku, Matthew, Gregory, Gareth, Gangatharan, Shane, Hapgood, Greg, Cochrane, Tara, Cheah, Chan, Gibbs, Simon, Wei, Andrew, Johnston, Anna, Greenwood, Matthew, Prince, H. Miles, Latimer, Maya, Berkahn, Leanne, Wight, Joel, Armytage, Tasman, Hamad, Nada
Vydáno 2021Text